Get the Stockscreener App
40.91
0.47%
0.19
After Hours:
39.58
-1.33
-3.25%
Janux Therapeutics Inc stock is traded at $40.91, with a volume of 972.29K.
It is up +0.47% in the last 24 hours and down -28.01% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$40.72
Open:
$41.35
24h Volume:
972.29K
Relative Volume:
0.93
Market Cap:
$2.40B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-35.27
EPS:
-1.16
Net Cash Flow:
$-37.82M
1W Performance:
-9.79%
1M Performance:
-28.01%
6M Performance:
-8.44%
1Y Performance:
+342.27%
1-Day Range:
$39.95
$42.00
1-Week Range:
$39.95
$47.46
52-Week Range:
$7.79
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
40.91 | 2.40B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8% - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Trading Down 3.5%Time to Sell? - MarketBeat
Long Term Trading Analysis for (JANX) - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Shares Down 3.5%Time to Sell? - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
JANX Makes Notable Cross Below Critical Moving Average - Nasdaq
BTIG affirms Buy on Janux stock, noting competitive positioning of JANX007 in mCRPC - Investing.com Canada
Janux Therapeutics (NASDAQ:JANX) Given "Outperform" Rating at William Blair - MarketBeat
Cancer data drive significant biopharma stock gains in a volatile 2024 - BioWorld Online
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock - MarketBeat
Janux Therapeutics CEO David Campbell sells $300,004 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CEO David Campbell sells $300,004 in stock - Investing.com India
Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results - Citeline News & Insights
Janux Therapeutics (NASDAQ:JANX) Shares Down 6.8%Here's Why - MarketBeat
Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha
Janux Therapeutics (NASDAQ:JANX) Trading Up 7%Still a Buy? - MarketBeat
Objective long/short (JANX) Report - Stock Traders Daily
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of Stock - MarketBeat
Janux Therapeutics chief business officer sells $731,785 in stock By Investing.com - Investing.com Canada
Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN
Viking stock among buyout targets: Oppenheimer (VKTX:NASDAQ) - Seeking Alpha
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
Lifesci Capital Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-Buy - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,404,750.00 in Stock - MarketBeat
Janux therapeutics CEO David Campbell sells $1.4 million in stock By Investing.com - Investing.com Nigeria
Janux therapeutics CEO David Campbell sells $1.4 million in stock - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Geode Capital Management LLC - MarketBeat
How the (JANX) price action is used to our Advantage - Stock Traders Daily
StockWatch: Wall Street’s Leaders and Laggards of 2024 - Genetic Engineering & Biotechnology News
Wellington Management Group LLP Trims Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $89.90 - MarketBeat
State Street Corp Sells 40,056 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Barclays PLC - MarketBeat
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Scrip
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Nets $350M in Stock Sale - San Diego Business Journal
Neo Ivy Capital Management Buys Shares of 20,674 Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Navigating 10 Analyst Ratings For Janux Therapeutics - Benzinga
Charles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Polar Asset Management Partners Inc. Buys New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Point72 Asset Management L.P. Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - StockTitan
Revolution , Janux prep for next steps with follow-on cash - BioCentury
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to $350 Million Underwritten Public Offering - Wilson Sonsini
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
Janux Therapeutics prices $350M securities offering - MSN
Readystate Asset Management LP Acquires New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
JANX Stock Hits Record High on Prostate Cancer Study Data - MSN
Samsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):